A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
38,396actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-06-13 | actual | When the study began enrolling |
| Primary completion | 2025-08-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-31 | actual | The whole study's end, after follow-up |
| First posted | 2022-06-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Rheumatoid Arthritis (RA)
- Psoriatic Arthritis (PsA)
Primary outcomes
what the primary-completion date above is the date OFIncidence Rates of Overall Malignancies
measured Up to 5 years
Incidence Rates of Melanoma
measured Up to 5 years
Incidence Rates of Non-melanoma Skin Cancer
measured Up to 5 years
Incidence Rates of Basal Cell Carcinoma
measured Up to 5 years
Incidence Rates of Squamous Cell Carcinoma
measured Up to 5 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed